Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged.

This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines, that go beyond what have traditionally been investigated in TB.    

Deadlines:

  • Application Due Date(s): January 14, 2019; January 14, 2020; January 14, 2021
  • AIDS Application Due Date(s): January 14, 2019; January 14, 2020; January 14, 2021

​PAR-18-923 Expiration Date January 15, 2021

Agency Website

Amount

$275,000

Amount Description

Application budgets are limited to $275,000 direct costs over two years, with no more than $200,000 direct costs being requested in a single year.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

January 14, 2020